Background And Objective: Many developed and non-developed countries worldwide suffer from cancer-related fatal diseases. In particular, the rate of breast cancer in females increases daily, partially due to unawareness and undiagnosed at the early stages. A proper first breast cancer treatment can only be provided by adequately detecting and classifying cancer during the very early stages of its development. The use of medical image analysis techniques and computer-aided diagnosis may help the acceleration and the automation of both cancer detection and classification by also training and aiding less experienced physicians. For large datasets of medical images, convolutional neural networks play a significant role in detecting and classifying cancer effectively.
Methods: This article presents a novel computer-aided diagnosis method for breast cancer classification (both binary and multi-class), using a combination of deep neural networks (ResNet 18, ShuffleNet, and Inception-V3Net) and transfer learning on the BreakHis publicly available dataset.
Results And Conclusions: Our proposed method provides the best average accuracy for binary classification of benign or malignant cancer cases of 99.7%, 97.66%, and 96.94% for ResNet, InceptionV3Net, and ShuffleNet, respectively. Average accuracies for multi-class classification were 97.81%, 96.07%, and 95.79% for ResNet, Inception-V3Net, and ShuffleNet, respectively.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.cmpb.2022.106951 | DOI Listing |
Biomol Biomed
January 2025
Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey.
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study.
View Article and Find Full Text PDFClin Cancer Res
January 2025
Mater Research Institute - University of Queensland, Woolloongabba, Qld, Australia.
Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer.
Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients (119 triple-negative breast cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER2-targeting ADC T-DM1.
Clin Cancer Res
January 2025
Massachusetts General Hospital Cancer Center, Boston, MA, United States.
Background: Race/ethnicity may affect outcomes in metastatic breast cancer (MBC) due to biological and social determinants. We evaluated the impact of race/ethnicity on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with MBC.
Methods: A retrospective study of patients with MBC who underwent cell-free DNA testing (cfDNA, Guardant360â, 74 gene panel) between 11/2016 and 11/2020 was conducted.
Endocrine
January 2025
Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
The word "cancer" evokes myriad emotions, ranging from fear and despair to hope and determination. Cancer is aptly defined as a complex and multifaceted group of diseases that has unapologetically led to the loss of countless lives and affected innumerable families across the globe. The battle with cancer is not only a physical battle, but also an emotional, as well as a psychological skirmish for patients and for their loved ones.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Purpose: Individuals with metastatic breast cancer (MBC) may live with their disease for many years. We initiated the Johns Hopkins Hope at Hopkins Clinic to assess the needs and optimize the care of these patients.
Patients And Methods: Patients with MBC who agreed to participate in the Clinic in addition to usual care completed patient-reported outcome (PRO) surveys.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!